RxDoctor Payments Data

Luis Curbelo Cunill, APRN

Nurse Practitioner · Miami, FLNPI 1750979803

Payments from drug & device makers

$5,250in general payments, 2019–2025

Across 264 payments — averaging $19.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$924
  • Johnson & Johnson$538
  • Teva Pharmaceuticals USA, Inc.$500
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$490
  • Almatica Pharma LLC$410
  • Neurocrine Biosciences, Inc.$402
  • plus $2K from 11 others

What the payments were for

  • Food & beverage$5,14098%
  • Education$1092%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,250 in reported general payments places this provider in the 90th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$19,237
Medicare patients
99
Services billed
205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole33$53,793
Abilify MaintenaAripiprazole19$53,193
VraylarCariprazine Hcl20$26,896
TrintellixVortioxetine Hydrobromide38$20,259
LybalviOlanzapine/Samidorphan Malate11$18,057
AuvelityDextromethorphan Hbr/Bupropion25$15,386
Aripiprazole239$13,542
Quetiapine Fumarate531$5,733
Lurasidone Hcl43$5,471
Clonazepam549$4,677
Trazodone Hcl648$4,526
Temazepam313$3,533
Chlorpromazine Hcl20$3,094
Alprazolam575$2,724
Escitalopram Oxalate536$2,722

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$924$106,98652 claims
AbbVieVraylar$90$26,89620 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$363$20,25938 claims
Alkermes, Inc.Lybalvi$359$18,05711 claims
Axsome Therapeutics, Inc.Auvelity$173$15,38625 claims
Almatica Pharma LLCSertraline Hcl$410$1,376416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →